TECTONIC THERAPEUTIC, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.47 USD | -0.12% |
|
-3.17% | +0.92% |
| Jun. 20 | Avrobio Closes Merger With Tectonic Therapeutic | MT |
| Jun. 20 | Tectonic Therapeutic, Inc. announced that it has received $96.599856 million in funding from Tas Partners, LLC | CI |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 242.7 | - | - |
| Enterprise Value (EV) 1 | 242.7 | 242.7 | 242.7 |
| P/E ratio | -2.37 x | -3.53 x | -3.07 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | - | - | - |
| EV / FCF | -4.26 x | -3.62 x | -2.82 x |
| FCF Yield | -23.5% | -27.6% | -35.4% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 14,734 | - | - |
| Reference price 2 | 16.47 | 16.47 | 16.47 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | - | -59.83 | -75.02 | -92.56 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -42.82 | -60.56 | -75.02 | -92.56 |
| Net income 1 | -42.82 | -60.56 | -75.02 | -92.56 |
| Net margin | - | - | - | - |
| EPS 2 | - | -6.960 | -4.665 | -5.365 |
| Free Cash Flow 1 | - | -57 | -67 | -86 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -14.36 | -15.67 | -17.32 | -17.77 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -14.23 | -15.54 | -17.18 | -17.77 |
| Net income 1 | -14.23 | -15.54 | -17.18 | -17.77 |
| Net margin | - | - | - | - |
| EPS 2 | -1.955 | -1.030 | -1.105 | -1.130 |
| Dividend per Share | - | - | - | - |
| Announcement Date | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -57 | -67 | -86 |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 2 | 3 | 4 |
| Capex / Sales | - | - | - | - |
| Announcement Date | 3/26/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
16.47
USD
Average target price
76
USD
Spread / Average Target
+361.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.92% | 243M | |
| +15.20% | 121B | |
| +19.67% | 113B | |
| +18.95% | 26.02B | |
| -23.86% | 19.39B | |
| -19.03% | 15.91B | |
| -20.90% | 15.09B | |
| -46.14% | 15.06B | |
| +63.85% | 14.93B | |
| +4.49% | 13.85B |
- Stock Market
- Equities
- AVRO Stock
- Financials Tectonic Therapeutic, Inc.
